[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:oculopharyngeal-muscular-dystrophy":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":21,"states":22},"Oculopharyngeal Muscular Dystrophy",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06185673","A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:39.267524Z","2026-05-05T02:43:27.284375Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford",[],"2026-08-26T02:17:29.353236Z","2026-05-13T02:55:06.077983Z",[],[]]